In Europe, the Committee for Medicinal Products for Human Use (CHMP) adopted positive opinions for cemiplimab as monotherapy in lung cancer and basal cell carcinoma.
International Approvals
EU Panel Likes Monotherapy Cemiplimab for Two Cancers
In Europe, the Committee for Medicinal Products for Human Use (CHMP) adopted positive opinions for cemiplimab as monotherapy in lung cancer and basal cell carcinoma.
International Approvals
